RECOMBINANT VACCINE MARKET ANALYSIS

Recombinant Vaccine Market, by Product Type (Subunit Recombinant Vaccine, Attenuated Recombinant Vaccine, Vector Recombinant Vaccine), by Disease Type (Infectious Disease, Cancer, Allergy, and others), by End User (Recombinant Human Vaccines and Animal Recombinant Vaccine (Poultry, Companion Animal Vaccines, Livestock, Porcine, and Aquaculture Vaccines)), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Jun 2022
Code : CMI455
Pages :156
Formats :
Excel and PDF
Industry : Biotechnology

Leading Companies

Global Recombinant Vaccines Market: Key Developments

In June 1, 2022, Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 11,345,896 to the company on May 31, 2022. This patent, entitled ‘Synthetic Chimeric Poxviruses’, which include claims covering synthetic horsepox virus, the basis for the company’s TNX-8011 vaccine in development to protect against monkeypox and smallpox and for the company’s recombinant pox virus (RPV) platform to protect against other pathogens, including SARS-CoV-2.

In June 1, 2022, VBI Vaccines Inc., a biopharmaceutical company, announced that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) had granted marketing authorization for PreHevbri [Hepatitis B vaccine (recombinant, adsorbed)] for active immunization against infection caused by all known subtypes of the hepatitis B virus (HBV) in adults.

Key Players

Major players operating in the global recombinant vaccines market include Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi, GSK plc., GC Biopharma, Bayer AG, Bharat Biotech, Serum Institute of India Pvt. Ltd., Sartorius AG, Johnson & Johnson Services, Inc., and Bio Farma.